Background: This study aimed to determine whether a shorter high-dose rifampicin regimen is non-inferior to the standard 6-month tuberculosis regimen. Methods: This multicenter, randomized, open-label, non-inferiority trial enrolled participants with respiratory specimen positivity by Xpert MTB/RIF assay or Mycobacterium tuberculosis culture without rifampicin-resistance. Participants were randomized at 1:1 to the investigational or control group. The investigational group received high-dose rifampicin (30 mg/kg/day), isoniazid, and pyrazinamide until culture conversion, followed by high-dose rifampicin and isoniazid for 12 weeks. The control group received the standard 6-month regimen. The primary outcome was the rate of unfavorable outcomes at 18 months post-randomization. The non-inferiority margin was set at <6% difference in unfavorable outcomes rates. The study is registered with ClinicalTrials.gov (NCT04485156) Results: Between 4 November 2020 and 3 January 2022, 76 participants were enrolled. Of these, 58 were included in the modified intention-to-treat analysis. Unfavorable outcomes occurred in 10 (31.3%) of 32 in the control group and 10 (38.5%) of 26 in the investigational group. The difference was 7.2% (95% confidence interval, ∞ to 31.9%), failing to prove non-inferiority. Serious adverse events and grade 3 or higher adverse events did not differ between the groups. Conclusion The shorter high-dose rifampicin regimen failed to demonstrate non-inferiority but had an acceptable safety profile.

Background: This study aimed to determine whether a shorter high-dose rifampicin regimen is non-inferior to the standard 6-month tuberculosis regimen. Methods: This multicenter, randomized, open-label, non-inferiority trial enrolled participants with respiratory specimen positivity by Xpert MTB/RIF assay or Mycobacterium tuberculosis culture without rifampicin-resistance. Participants were randomized at 1:1 to the investigational or control group. The investigational group received high-dose rifampicin (30 mg/kg/day), isoniazid, and pyrazinamide until culture conversion, followed by high-dose rifampicin and isoniazid for 12 weeks. The control group received the standard 6-month regimen. The primary outcome was the rate of unfavorable outcomes at 18 months post-randomization. The non-inferiority margin was set at <6% difference in unfavorable outcomes rates. The study is registered with ClinicalTrials.gov (NCT04485156) Results: Between 4 November 2020 and 3 January 2022, 76 participants were enrolled. Of these, 58 were included in the modified intention-to-treat analysis. Unfavorable outcomes occurred in 10 (31.3%) of 32 in the control group and 10 (38.5%) of 26 in the investigational group. The difference was 7.2% (95% confidence interval, ∞ to 31.9%), failing to prove non-inferiority. Serious adverse events and grade 3 or higher adverse events did not differ between the groups. Conclusion The shorter high-dose rifampicin regimen failed to demonstrate non-inferiority but had an acceptable safety profile.

Background: This study aimed to determine whether a shorter high-dose rifampicin regimen is non-inferior to the standard 6-month tuberculosis regimen. Methods: This multicenter, randomized, open-label, non-inferiority trial enrolled participants with respiratory specimen positivity by Xpert MTB/RIF assay or Mycobacterium tuberculosis culture without rifampicin-resistance. Participants were randomized at 1:1 to the investigational or control group. The investigational group received high-dose rifampicin (30 mg/kg/day), isoniazid, and pyrazinamide until culture conversion, followed by high-dose rifampicin and isoniazid for 12 weeks. The control group received the standard 6-month regimen. The primary outcome was the rate of unfavorable outcomes at 18 months post-randomization. The non-inferiority margin was set at <6% difference in unfavorable outcomes rates. The study is registered with ClinicalTrials.gov (NCT04485156) Results: Between 4 November 2020 and 3 January 2022, 76 participants were enrolled. Of these, 58 were included in the modified intention-to-treat analysis. Unfavorable outcomes occurred in 10 (31.3%) of 32 in the control group and 10 (38.5%) of 26 in the investigational group. The difference was 7.2% (95% confidence interval, ∞ to 31.9%), failing to prove non-inferiority. Serious adverse events and grade 3 or higher adverse events did not differ between the groups. Conclusion The shorter high-dose rifampicin regimen failed to demonstrate non-inferiority but had an acceptable safety profile.

Background: This study aimed to determine whether a shorter high-dose rifampicin regimen is non-inferior to the standard 6-month tuberculosis regimen. Methods: This multicenter, randomized, open-label, non-inferiority trial enrolled participants with respiratory specimen positivity by Xpert MTB/RIF assay or Mycobacterium tuberculosis culture without rifampicin-resistance. Participants were randomized at 1:1 to the investigational or control group. The investigational group received high-dose rifampicin (30 mg/kg/day), isoniazid, and pyrazinamide until culture conversion, followed by high-dose rifampicin and isoniazid for 12 weeks. The control group received the standard 6-month regimen. The primary outcome was the rate of unfavorable outcomes at 18 months post-randomization. The non-inferiority margin was set at <6% difference in unfavorable outcomes rates. The study is registered with ClinicalTrials.gov (NCT04485156) Results: Between 4 November 2020 and 3 January 2022, 76 participants were enrolled. Of these, 58 were included in the modified intention-to-treat analysis. Unfavorable outcomes occurred in 10 (31.3%) of 32 in the control group and 10 (38.5%) of 26 in the investigational group. The difference was 7.2% (95% confidence interval, ∞ to 31.9%), failing to prove non-inferiority. Serious adverse events and grade 3 or higher adverse events did not differ between the groups. Conclusion The shorter high-dose rifampicin regimen failed to demonstrate non-inferiority but had an acceptable safety profile.

Background: This study aimed to determine whether a shorter high-dose rifampicin regimen is non-inferior to the standard 6-month tuberculosis regimen. Methods: This multicenter, randomized, open-label, non-inferiority trial enrolled participants with respiratory specimen positivity by Xpert MTB/RIF assay or Mycobacterium tuberculosis culture without rifampicin-resistance. Participants were randomized at 1:1 to the investigational or control group. The investigational group received high-dose rifampicin (30 mg/kg/day), isoniazid, and pyrazinamide until culture conversion, followed by high-dose rifampicin and isoniazid for 12 weeks. The control group received the standard 6-month regimen. The primary outcome was the rate of unfavorable outcomes at 18 months post-randomization. The non-inferiority margin was set at <6% difference in unfavorable outcomes rates. The study is registered with ClinicalTrials.gov (NCT04485156) Results: Between 4 November 2020 and 3 January 2022, 76 participants were enrolled. Of these, 58 were included in the modified intention-to-treat analysis. Unfavorable outcomes occurred in 10 (31.3%) of 32 in the control group and 10 (38.5%) of 26 in the investigational group. The difference was 7.2% (95% confidence interval, ∞ to 31.9%), failing to prove non-inferiority. Serious adverse events and grade 3 or higher adverse events did not differ between the groups. Conclusion The shorter high-dose rifampicin regimen failed to demonstrate non-inferiority but had an acceptable safety profile.

Purpose: This study aimed to assess dementia awareness and educational needs among elderly care facility workers and to explore their experiences in caring for older adults with dementia through a mixed-methods approach. Methods: From May 1 to 31, 2023, 311 workers from dementia-related institutions in S City participated in a survey. Following the quantitative phase, 10 individuals participated in focus group interviews to further explore their experiences and needs. Quantitative data were analyzed using SPSS/WIN 25.0, and thematic analysis was applied to qualitative data. Results: The average dementia awareness score was 0.83±0.13 (out of 12), with the highest correct response rate (93%) in the "prevention and t reatment" category. The most requested education topics included managing "agitation and aggression" and improving "communication" skills. Qualitative analysis revealed two main themes with five subthemes, capturing staff experiences in dementia care and their perceived educational needs. Conclusion The findings highlight a strong demand for practical, structured training programs tailored to address behavioral management and communication challenges faced by facility staff.

Purpose: This study aimed to assess dementia awareness and educational needs among elderly care facility workers and to explore their experiences in caring for older adults with dementia through a mixed-methods approach. Methods: From May 1 to 31, 2023, 311 workers from dementia-related institutions in S City participated in a survey. Following the quantitative phase, 10 individuals participated in focus group interviews to further explore their experiences and needs. Quantitative data were analyzed using SPSS/WIN 25.0, and thematic analysis was applied to qualitative data. Results: The average dementia awareness score was 0.83±0.13 (out of 12), with the highest correct response rate (93%) in the "prevention and t reatment" category. The most requested education topics included managing "agitation and aggression" and improving "communication" skills. Qualitative analysis revealed two main themes with five subthemes, capturing staff experiences in dementia care and their perceived educational needs. Conclusion The findings highlight a strong demand for practical, structured training programs tailored to address behavioral management and communication challenges faced by facility staff.

Purpose: This study aimed to assess dementia awareness and educational needs among elderly care facility workers and to explore their experiences in caring for older adults with dementia through a mixed-methods approach. Methods: From May 1 to 31, 2023, 311 workers from dementia-related institutions in S City participated in a survey. Following the quantitative phase, 10 individuals participated in focus group interviews to further explore their experiences and needs. Quantitative data were analyzed using SPSS/WIN 25.0, and thematic analysis was applied to qualitative data. Results: The average dementia awareness score was 0.83±0.13 (out of 12), with the highest correct response rate (93%) in the "prevention and t reatment" category. The most requested education topics included managing "agitation and aggression" and improving "communication" skills. Qualitative analysis revealed two main themes with five subthemes, capturing staff experiences in dementia care and their perceived educational needs. Conclusion The findings highlight a strong demand for practical, structured training programs tailored to address behavioral management and communication challenges faced by facility staff.

Purpose: This study aimed to assess dementia awareness and educational needs among elderly care facility workers and to explore their experiences in caring for older adults with dementia through a mixed-methods approach. Methods: From May 1 to 31, 2023, 311 workers from dementia-related institutions in S City participated in a survey. Following the quantitative phase, 10 individuals participated in focus group interviews to further explore their experiences and needs. Quantitative data were analyzed using SPSS/WIN 25.0, and thematic analysis was applied to qualitative data. Results: The average dementia awareness score was 0.83±0.13 (out of 12), with the highest correct response rate (93%) in the "prevention and t reatment" category. The most requested education topics included managing "agitation and aggression" and improving "communication" skills. Qualitative analysis revealed two main themes with five subthemes, capturing staff experiences in dementia care and their perceived educational needs. Conclusion The findings highlight a strong demand for practical, structured training programs tailored to address behavioral management and communication challenges faced by facility staff.

Purpose: This study aimed to assess dementia awareness and educational needs among elderly care facility workers and to explore their experiences in caring for older adults with dementia through a mixed-methods approach. Methods: From May 1 to 31, 2023, 311 workers from dementia-related institutions in S City participated in a survey. Following the quantitative phase, 10 individuals participated in focus group interviews to further explore their experiences and needs. Quantitative data were analyzed using SPSS/WIN 25.0, and thematic analysis was applied to qualitative data. Results: The average dementia awareness score was 0.83±0.13 (out of 12), with the highest correct response rate (93%) in the "prevention and t reatment" category. The most requested education topics included managing "agitation and aggression" and improving "communication" skills. Qualitative analysis revealed two main themes with five subthemes, capturing staff experiences in dementia care and their perceived educational needs. Conclusion The findings highlight a strong demand for practical, structured training programs tailored to address behavioral management and communication challenges faced by facility staff.